Glucosamine combined with non-steroidal anti-inflammatory drugs for treatment of osteoarthritis

doi:10.3877/cma.j.issn.1674-0785.2017.22.008

Abstract

Abstract:

Osteoarthritis (OA) is a clinically common degenerative disease in middle-aged and elderly people, with the knee joint being the most frequently affected. Pharmacological treatment is one of the main means of treatment for knee osteoarthritis (KOA). Non-steroidal anti-inflammatory drugs (NSAIDs) and glucosamine are common drugs for treatment of KOA. Clinically, the combination of glucosamine and NSAIDs is very common. However, there have been no review articles discussing the combination of glucosamine and NSAIDs for treatment of KOA. This paper summarizes the latest basic, clinical, and epidemiological studies on the combined use of the two drugs in the treatment of KOA. Based on the current research evidence, the combination of the two drugs in the treatment of KOA has significant short-term clinical effects, and long-term use can reduce the use of NSAIDs. However, the advantages and disadvantages should be considered comprehensively, and more reliable research results are needed to guide the clinical use of these drugs.

Key words: Non-steroid anti-inflammatory drug, Osteoarthritis, Glucosamine

Guangzong Ren, Xiaochun Wei. Glucosamine combined with non-steroidal anti-inflammatory drugs for treatment of osteoarthritis[J]. Chinese Journal of Clinicians(Electronic Edition), 2017, 11(22): 2418-2422.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2017.22.008

https://zhlcyszz.cma-cmc.com.cn/EN/Y2017/V11/I22/2418

References 51

[1]	Zeng QY, Chen R, Darmawan J, et al. Rheumatic diseases in China [J]. Arthritis Res Ther, 2008, 10(1): R17.
[2]	Felson DT. Comparing the prevalence of rheumatic diseases in China with the rest of the world [J]. Arthritis Res Ther, 2008, 10(1): 106.
[3]	Prietoalhambra D, Wilson N. Use of drug combinations in patients with osteoarthritis: a population-based cohort study [J]. Osteoarthritis and Cartilage, 2013, 21(10): s160.
[4]	Kucharz EJ, Kovalenko V, Szántó S, et al. A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes [J]. Curr Med Res Opin, 2016, 32(6): 997-1004.
[5]	Bruyère O, Altman RD, Reginster JY. Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: evidence from real-life setting trials and surveys [J]. Semin Arthritis Rheum, 2016, 45(4 Suppl): S12-S17.
[6]	邱贵兴, 翁习生, 张克, 等. 盐酸/硫酸氨基葡萄糖治疗骨关节炎的平行对照临床研究 [J].中华医学杂志, 2005, 85(43): 49-52.
[7]	Rahman S, Malcoun A. Nonsteroidal anti-inflammatory drugs, cyclooxygenase-2, and the kidneys[J]. Prim Care, 2014, 41(4): 803-821.
[8]	Sehgal A, Sehgal VK, Singh R. Comparison of efficacy and tolerability of aceclofenac and diclofenac in osteoarthritis of knee joint [J]. Int J Med and Dent Sci, 2015, 4(2): 745-750.
[9]	Pountos I, Georgouli T, Bird H, et al. Nonsteroidal anti-inflammatory drugs: Prostaglandins, indications, and side effects [J]. Int J Interferon Cytokine Mediat Res, 2011, 3(1) :19-27.
[10]	Hafezi-Nejad N, Guermazi A, Roemer FW et al. Long term use of analgesics and risk of osteoarthritis progressions and knee replacement: propensity score matched cohort analysis of data from the Osteoarthritis Initiative [J]. Osteoarthritis and Cartilage, 2016, 24(4): 597-604.
[11]	Young D. FDA ponders future of NSAIDs: Pfizer reluctantly withdraws Bextra [J]. Am J Health Syst Pharm, 2005, 62(10): 997-1000.
[12]	Rovati LC, Girolami F, D ′Amato M, et al. Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study [J]. Semin Arthritis Rheum, 2016, 45(4 Suppl): S34-S41.
[13]	Bertin P, Taieb C. NSAID-sparing effect of glucosamine hydrochloride in patients with knee osteoarthritis: an analysis of data from a French database [J]. Curr Med Res Opin, 2014, 30(2): 271-277.
[14]	Martel-Pelletier J, Roubille C, Abram F, et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort [J]. Ann Rheum Dis, 2015, 74(3): 547-556.
[15]	National Collaborating Centre for Chronic Conditions (UK). Osteoarthritis: National Clinical Guideline for Care and Management in Adults [M]. London: Royal College of Physicians (UK), 2008.
[16]	Lapane KL, Yang S, Driban JB, et al. Effects of prescription non-steroidal anti-inflammatory agents on symptoms and disease progression among patients with knee osteoarthritis [J]. Arthritis Rheumatol, 2015, 67(3): 724-732.
[17]	Panahifar A, Jaremko JL, Tessier AG, et al. Development and reliability of a multi-modality scoring system for evaluation of disease progression in pre-clinical models of osteoarthritis: celecoxib may possess disease-modifying properties [J]. Osteoarthritis Cartilage, 2014, 22(10): 1639-1650.
[18]	Ding C, Cicuttini F, Jones G. Do NSAID Affect Longitudinal Changes in Knee Cartilage Volume and Knee Cartilage Defects in Older Adults? [J]. Am J Med, 2009, 122(9): 836-842.
[19]	Neogi T, Felson D, Niu J, et al. Association between radiographic features of knee osteoarthritis and pain: results from two cohort studies [J]. BMJ. 2009, 339: b2844.
[20]	Nakamura H. Application of glucosamine on human disease—Osteoarthritis [J]. Carbohydrate Polymers, 2011, 84(2):835-839.
[21]	Forestier R, Francon A, Briole V, et al. Prevalence of generalized osteoarthritis in a population with knee osteoarthritis [J]. Joint Bone Spine. 2011, 78(3): 275-278.
[22]	Burian M, Geisslinger G. Review COX-dependent mechanisms involved in the antinociceptive action of NSAID at central and peripheral sites [J]. Pharmacol Ther, 2005, 107(2): 139-154.
[23]	Tallarida RJ, Cowan A, Raffa RB. Antinociceptive synergy, additivity, and subadditivity with combinations of oral glucosamine plus nonopioid analgesics in mice [J]. J Pharmacol Exp Ther, 2003, 307(2): 699-704.
[24]	Davishnia NV, Zupanets IA, Shebeko SK, et al. The influence of glucosamine and Ketoprofen combination in the form of cream-gel on connective tissue metabolism indicators of rats with experimental osteoarthritis [J]. The Pharma Innovation Journal, 2015, 3(12): 8-11.
[25]	Davishnia NV, Zupanets IA, Shebeko SK, et al. The modification of anti-inflammatory properties of the combined use of NSAID and glucosamine in topical dosage form for degenerative and inflammatory joint diseases treatment [J]. Clin Ther, 2016,38(10S): e24.
[26]	丁国强. 盐酸氨基葡萄糖与对乙酰氨基酚治疗膝骨关节炎的临床疗效观察 [J]. 华西医学, 2013, 28(12): 1840-1842.
[27]	Ruane R, Griffiths P. Glucosamine therapy compared to ibuprofen for joint pain [J]. Br J Community Nurs, 2002 ,7(3): 148-152.
[28]	Selvan T, Rajiah K, Nainar MS, et al. A clinical study on glucosamine sulfate versus combination of glucosamine sulfate and NSAID in mild to moderate knee osteoarthritis [J]. Scientific World Journal, 2012, 2012: 902676.
[29]	高延军, 安久利, 赵广. 盐酸氨基葡萄糖联合洛索洛芬钠治疗膝骨性关节炎临床观察 [J]. 中国骨肿瘤骨病, 2010, 9(3): 248-251.
[30]	余素君, 纳世丽, 魏薇, 等. 盐酸氨基葡萄糖联合非甾体抗炎药治疗中度膝关节骨关节炎的临床研究 [J]. 现代生物医学进展, 2015, 15(10): 1919-1922.
[31]	Tieppo Francio V, Davani S, Towery C, et al. Oral versus topical diclofenac sodium in the treatment of osteoarthritis [J]. J Pain Palliat Care Pharmacother, 2017, 31(2): 113-120.
[32]	唐令. 不同药物治疗膝骨性关节炎综合症状的效果 [J]. 中国医药导报, 2015, 12(15): 132-135.
[33]	周光宇. 双氯芬酸和盐酸氨基葡萄糖联用对膝关节骨关节炎的效果观察 [J]. 医学信息, 2015(48): 227-227.
[34]	王华, 王宪英. 硫酸氨基葡萄糖联合非甾体抗炎药治疗中度骨关节炎的研究 [J]. 河北医药, 2014, 36(8): 1159-1161.
[35]	Babladikar A, Koppula A, Aravind Swami P, et al. Effectiveness of glucosamine as supplement to aceclofenac in the reduction of pain among knee osteoarthritic patients [J]. Indo American Journal of Pharmaceutical Research, 2016, 6(5): 5364-5378.
[36]	张瑞萍. 双氯芬酸钠贴片联合硫酸氨基葡萄糖治疗骨性关节炎的不良反应及疗效分析 [J]. 中国处方药, 2016, 14(7): 46-47.
[37]	卢宏伟, 罗飞, 侯天勇, 等. 硫酸氨基葡萄糖联合非甾体抗炎药在轻中度膝骨关节炎中的作用 [J]. 中国医药导报, 2016, 13(17): 137-139, 148.
[38]	甘祝梅, 黄珠砂. 非甾体抗炎药物联合氨基葡萄糖治疗膝骨性关节炎的临床研究 [J]. 中国药物经济学, 2013(4): 66-68.
[39]	温旭升. 氨基葡萄糖胶囊联合美洛昔康治疗退行性膝关节炎临床疗效观察 [J]. 国际医药卫生导报, 2013, 19(4): 522-523.
[40]	陈璐佳, 欧大明. 盐酸氨基葡萄糖片联合美洛昔康片治疗膝关节骨关节炎临床分析 [J].淮海医药, 2017, 35(1): 82-84.
[41]	王娟. 美洛昔康联合盐酸氨基葡萄糖治疗膝关节骨性关节炎51例[J]. 感染、炎症、修复, 2016, 17(4): 236-237.
[42]	Puljak L, Marin A, Vrdoljak D, et al. Celecoxib for osteoarthritis [J]. Cochrane Database Syst Rev, 2017, 5: CD009865.
[43]	傅文辉, 张梅秀.硫酸氨基葡萄糖联合塞来昔布治疗骨关节炎疗效分析[J].海峡药学, 2016, 28(2): 184-185.
[44]	赵鹏, 王磊, 郑鹏. 塞来昔布与盐酸氨基葡萄糖联合治疗膝骨关节炎临床观察 [J]. 国际医药卫生导报, 2014, 20(1): 68-70.
[45]	李伟, 赵育红, 武长江, 等. 盐酸氨基葡萄糖联合塞来昔布对膝关节骨性关节炎的临床疗效观察 [J]. 现代生物医学进展, 2015, 15(2): 281-283.
[46]	王光勇, 方忠, 敦先礼. 塞来昔布联合氨基葡萄糖治疗膝骨性关节炎的疗效观察 [J]. 医药导报, 2006, 25(12): 1280-1283.
[47]	李明辉, 刘洋, 王彩民, 等. 盐酸氨基葡萄糖联合塞来昔布治疗膝骨性关节炎的随机对照[J]. 中国组织工程研究, 2013, 17(43): 7654-7660.
[48]	Stichtenoth DO. The second generation of COX-2 inhibitors: clinical pharmacological point of view [J]. Mini Rev Med Chem, 2004, 4(6): 617-24.
[49]	王少华, 连鸿凯, 宋树春, 等. 依托考昔联合盐酸氨基葡萄糖治疗膝骨关节炎的疗效观察[J]. 医药论坛杂志, 2012, 33(7): 93-94.
[50]	印卫锋, 陈苏, 李文凯, 等. 硫酸氨基葡萄糖联合依托考昔治疗膝关节骨性关节炎的临床研究 [J]. 骨科, 2016, 7(3): 190-194.
[51]	Laires PA, Laíns J, Miranda LC, et al. Inadequate pain relief among patients with primary knee osteoarthritis [J]. Rev Bras Reumatol Engl Ed, 2017, 57(3): 229-237.

Please choose a citation manager

Content to export